Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 0.91 |
| ▸ | MMP9 | P14780 | 19/20 | 0.91 |
| ▸ | MMP1 | P03956 | 6/20 | 0.91 |
| ▸ | MMP3 | P08254 | 6/20 | 0.91 |
| ▸ | MMP7 | P09237 | 6/20 | 0.91 |
| ▸ | MMP13 | P45452 | 6/20 | 0.91 |
| ▸ | MMP8 | P22894 | 6/20 | 0.70 |
| ▸ | MMP12 | P39900 | 6/20 | 0.70 |
| ▸ | MMP14 | P50281 | 6/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417025 | 0.96 | MMP2 (0.88) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6419967 | 0.96 | MMP2 (0.88) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6412212 | 0.89 | MMP2 (0.73) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6417083 | 0.89 | MMP2 (0.82) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL7425260 | 0.89 | MMP2 (0.72) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6414627 | 0.87 | MMP2 (0.84) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6414105 | 0.86 | MMP2 (0.71) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6419178 | 0.84 | MMP2 (0.80) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL27540116 | 0.83 | MMP2 (0.73) | MMP2MMP9MMP1MMP3MMP7 | |
| SCHEMBL6413001 | 0.83 | MMP2 (0.72) | MMP2MMP9MMP1MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP1 20/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP1 20/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP9 1/4885MMP1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.